Central Nervous System Involvement in Patients with Diffuse Large B Cell Lymphoma: Analysis of the Risk Factors and Prognosis from a Single-Center Retrospective Cohort Study

References

• Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ, Go RS. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011. Am J Hematol. 2015;90:790–795. doi:10.1002/ajh.2408626096944
   PubMed Web of Science ®Google Scholar
• Abramson JS. High-dose chemotherapy and autologous stem -cell transplantation for secondary central nervous system lymphoma: many are called, but few are chosen. Haematologica. 2013;98:662–664. doi:10.3324/haematol.2013.08428523633540
   PubMed Web of Science ®Google Scholar
• Zhang J, Chen B, Xu X. Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis. Leuk Lymphoma. 2014;55(3 ):509–514. doi:10.3109/10428194.2013.81123923741977
   PubMed Web of Science ®Google Scholar
• Tai WM, Chung J, Tang PL, et al. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre-and post-rituximab. Ann Hematol. 2011;90:809–818. doi:10.1007/s00277-010-1150-721229246
   PubMed Web of Science ®Google Scholar
• Fletcher CD, Kahl BS. Central nervous system involvement in diffuse large B-cell lymphoma: an analysis of risks and prevention strategies in the post-rituximab era. Leuk Lymphoma. 2014;55(10 ):2228–2240. doi:10.3109/10428194.2013.86932624286262
   PubMed Web of Science ®Google Scholar
• Van Besien K, Ha CS, Murphy S, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood. 1998;91(4 ):1178–1184. doi:10.1006/bcmd.1998.01719454747
   PubMed Web of Science ®Google Scholar
• Kumar A, Vanderplas A, LaCasce AS, et al. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer. 2012;118(11 ):2944–2951. doi:10.1002/cncr.2658822006274
   PubMed Web of Science ®Google Scholar
• Schmitz N, Zeynalova S, Glass B, et al. CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group. Ann Oncol. 2012;23(5 ):1267–1273. doi:10.1093/annonc/mdr44021989328
   PubMed Web of Science ®Google Scholar
• Tomita N, Yokoyama M, Yamamoto W, et al. Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era. Cancer Sci. 2012;103(2 ):245–251.22044593
   PubMed Web of Science ®Google Scholar
• Hosein PJ, Maragulia JC, Salzberg MP, et al. A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. Br J Haematol. 2014;165(3 ):358–363. doi:10.1111/bjh.1275324467658
   PubMed Web of Science ®Google Scholar
• Herrera AF, Mei M, Low L, et al. Relapsed or refractory double-expressor and double-hit lymphomas have inferior progression-free survival after autologous stem-cell transplantation. J Clin Oncol. 2017;35(1 ):24–31. doi:10.1200/JCO.2016.68.274028034071
   PubMed Web of Science ®Google Scholar
• Riedell PA, Smith SM. Double hit and double expressors in lymphoma: definition and treatment. Cancer. 2018;124:4622–4632. doi:10.1002/cncr.3164630252929
   PubMed Web of Science ®Google Scholar
• Schmitz N, Zeynalova S, Nickelsen M, et al. CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Cli Oncol. 2016. doi:10.1200/JCO.2015.65.6520
   Google Scholar
• Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124(15 ):2354–2361. doi:10.1182/blood-2014-05-57896325161267
   PubMed Web of Science ®Google Scholar
• Oki Y, Noorani M, Lin P, et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014;166(6 ):891–901.doi:10.1111/bjh.1298224943107
   PubMed Web of Science ®Google Scholar
• Verrou E, Gerofotis A, Karampatzakis N, et al. CNS relapse in patients with DLBCL according to CNS-IPI score and the initial therapy. Hematol Oncol. 2017;35:353–354. doi:10.1002/hon.2439_106
   Google Scholar
• Savage KJ, Slack GW, Mottok A, et al. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood. 2016;127:2182–2188. doi:10.1182/blood-2015-10-67670026834242
   PubMed Web of Science ®Google Scholar
• Cheah CY, Herbert KE, O’Rourke K, et al. A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma. Br J Cancer. 2014;111(6 ):1072–1079. doi:10.1038/bjc.2014.40525072255
   PubMed Web of Science ®Google Scholar
• Feugier P, Virion JM, Tilly H, et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence or rituximab. Ann Oncol. 2004;15(1 ):129–133. doi:10.1093/annonc/mdh01314679132
   PubMed Web of Science ®Google Scholar
• Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood. 2009;113(17 ):3896–3902. doi:10.1182/blood-2008-10-18225319144985
   PubMed Web of Science ®Google Scholar
• Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol. 2009;21(5 ):1046–1052. doi:10.1093/annonc/mdp43219861575
   PubMed Web of Science ®Google Scholar
• Chihara D, Oki Y, Matsuo K, et al. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: analyses with competing risk regression model. Leuk Lymphoma. 2011;52(12 ):2270–2275. doi:10.3109/10428194.2011.59696621745170
   PubMed Web of Science ®Google Scholar
• Siegal T, Goldschmidt N. CNS prophylaxis in diffuse large B-cell lymphoma: if, when, how and for whom? Blood Rev. 2012;26(3 ):97–106. doi:10.1016/j.blre.2011.12.00122244544
   PubMed Web of Science ®Google Scholar
• Graber JJ, Omuro A. Primary central nervous system lymphoma: is there still a role for radiotherapy? Curr Opin Neurol. 2011;24(6 ):633–640. doi:10.1097/WCO.0b013e32834cbdef21968551
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Gupta NK, Mannis GN, LaMarre AK, Treseler P. How I treat CNS lymphomas. Blood. 2013;122(14 ):2318–2330. doi:10.1182/blood-2013-06-45308423963042
   PubMed Web of Science ®Google Scholar
• Fischer L, Korfel A, Kiewe P, Neumann M, Jahnke K, Thiel E. Systemic high- dose methotrexate plus ifosfamide is highly effective for central nervous system (CNS) involvement of lymphoma. Ann Hematol. 2009;88(2 ):133–139. doi:10.2214/AJR.07.391918679681
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009;374(9700 ):1512–1520. doi:10.1016/S0140-6736(09)61416-119767089
   PubMed Web of Science ®Google Scholar
• Bokstein F, Lossos A, Lossos IS, Siegal T. Central nervous system relapse of systemic non-Hodgkin’s lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy. Leuk Lymphoma. 2002;43(3 ):587–593. doi:10.1080/1042819029001209212002763
   PubMed Web of Science ®Google Scholar
• Wong ET, Tishler R, Barron L, Wu JK. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer. 2004;101(1 ):139–145. doi:10.1002/cncr.2033915221999
   PubMed Web of Science ®Google Scholar
• Peñalver F-J, Sancho J-M, de la Fuente A, et al. Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO). Haematologica. 2017;102(2 ):235–245. doi:10.3324/haematol.2016.14912027846613
   PubMed Web of Science ®Google Scholar